Skip to main content
. 2024 Jan 18;6(4):100999. doi: 10.1016/j.jhepr.2023.100999

Fig. 3.

Fig. 3

HBV DNA and pgRNA change from baseline in patients from study 202 (FAS; on-treatment phase).

Changes from baseline in (A) HBV DNA and (B) HBV pgRNA in study 211 from patients previously enrolled in study 202. ETV, entecavir; FAS, full analysis set; PBO, placebo; pgRNA, pregenomic RNA; TN, treatment-naive; VBR, vebicorvir.